Inter-observer reproducibility of HER2 immunohistochemical assessment and concordance with fluorescent in situ hybridization (FISH): pathologist assessment compared to quantitative image analysis

被引:72
作者
Turashvili, Gulisa [1 ]
Leung, Samuel [2 ]
Turbin, Dmitry [2 ]
Montgomery, Kelli [3 ]
Gilks, Blake [2 ]
West, Rob [3 ]
Carrier, Melinda [2 ]
Huntsman, David [2 ]
Aparicio, Samuel [1 ]
机构
[1] BC Canc Res Ctr, Mol Oncol & Breast Canc Program, Vancouver, BC, Canada
[2] Univ British Columbia, Genet Pathol Evaluat Ctr, Vancouver, BC V5Z 1M9, Canada
[3] Stanford Univ, Med Ctr, Dept Pathol, Stanford, CA 94305 USA
关键词
BREAST-CANCER; HER-2/NEU EXPRESSION; GENE AMPLIFICATION; TISSUE MICROARRAY; CARCINOMA; PROTEIN; HERCEPTEST; OVEREXPRESSION; ANTIBODIES; ISSUES;
D O I
10.1186/1471-2407-9-165
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Background: In breast cancer patients, HER2 overexpression is routinely assessed by immunohistochemistry (IHC) and equivocal cases are subject to fluorescent in situ hybridization ( FISH). Our study compares HER2 scoring by histopathologists with automated quantitation of staining, and determines the concordance of IHC scores with FISH results. Methods: A tissue microarray was constructed from 1,212 invasive breast carcinoma cases with linked treatment and outcome information. IHC slides were semi-quantitatively scored by two independent pathologists on a range of 0 to 3+, and also analyzed with an Ariol automated system by two operators. 616 cases were scorable by both IHC and FISH. Results: Using data from unequivocal positive (3+) or negative (0, 1+) results, both visual and automated scores were highly consistent: there was excellent concordance between two pathologists ( kappa = 1.000, 95% CI: 1-1), between two machines ( kappa = 1.000, 95% CI: 1-1), and between both visual and both machine scores ( kappa = 0.898, 95% CI: 0.775-0.979). Two pathologists successfully distinguished negative, positive and equivocal cases ( kappa = 0.929, 95% CI: 0.909-0.946), with excellent agreement with machine 1 scores ( kappa = 0.835, 95% CI: 0.806-0.862; kappa = 0.837, 95% CI: 0.81-0.862), and good agreement with machine 2 scores ( kappa = 0.698, 95% CI: 0.6723-0.723; kappa = 0.709, 95% CI: 0.684-0.732), whereas the two machines showed good agreement ( kappa = 0.806, 95% CI: 0.785-0.826). When comparing categorized IHC scores and FISH results, the agreement was excellent for visual 1 (kappa = 0.814, 95% CI: 0.768-0.856), good for visual 2 ( kappa = 0.763, 95% CI: 0.712-0.81) and machine 1 ( kappa = 0.665, 95% CI: 0.609-0.718), and moderate for machine 2 ( kappa = 0.535, 95% CI: 0.485-0.584). Conclusion: A fully automated image analysis system run by an experienced operator can provide results consistent with visual HER2 scoring. Further development of such systems will likely improve the accuracy of detection and categorization of membranous staining, making this technique suitable for use in quality assurance programs and eventually in clinical practice.
引用
收藏
页数:13
相关论文
共 65 条
[1]   IHC for Her2 with CBE356 antibody is a more accurate predictor of Her2 gene amplification by FISH than HercepTest™ in breast carcinoma [J].
Ainsworth, R ;
Bartlett, JMS ;
Going, JJ ;
Mallon, EA ;
Forsyth, A ;
Richmond, J ;
Angerson, W ;
Watters, A ;
Dunne, B .
JOURNAL OF CLINICAL PATHOLOGY, 2005, 58 (10) :1086-1090
[2]  
[Anonymous], 1994, An introduction to the bootstrap: CRC press
[3]  
[Anonymous], R Project for Statistical Computing (Version 3.0.2)
[4]  
Bishop JW, 2002, ANAL QUANT CYTOL, V24, P257
[5]   Enhanced accuracy and reliability of HER-2/neu immunohistochemical scoring using digital microscopy [J].
Bloom, K ;
Harrington, D .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2004, 121 (05) :620-630
[6]   Color realism and color science [J].
Byrne, A ;
Hilbert, DR .
BEHAVIORAL AND BRAIN SCIENCES, 2003, 26 (01) :3-+
[7]   HER-2 status in breast cancer - Correlation of gene amplification by FISH with immunohistochemistry expression using advanced cellular imaging system [J].
Ciampa, Armando ;
Xu, Bo ;
Ayata, Gamze ;
Baiyee, Daniel ;
Wallace, Jan ;
Wertheimer, Michael ;
Edmiston, Kathryn ;
Khan, Ashraf .
APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY, 2006, 14 (02) :132-137
[8]  
Diaz N M, 2001, Cancer Control, V8, P415
[9]   Comparison of immunohistochemical and fluorescence in situ hybridization assessment of HER-2 status in routine practice [J].
Dolan, M ;
Snover, D .
AMERICAN JOURNAL OF CLINICAL PATHOLOGY, 2005, 123 (05) :766-770
[10]   Analytical validation and interobserver reproducibility of EnzMet GenePro - A second-generation bright-field metallography assay for concomitant detection of HER2 gene status and protein expression in invasive carcinoma of the breast [J].
Downs-Kelly, E ;
Pettay, J ;
Hicks, D ;
Skacel, M ;
Yoder, B ;
Rybicki, L ;
Myles, J ;
Sreenan, J ;
Roche, P ;
Powell, R ;
Hainfeld, J ;
Grogan, T ;
Tubbs, R .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2005, 29 (11) :1505-1511